▶ Watch videos on how best NASH and NAFLD can be managed.
Dive into the transformative world of liver health with Prof. Vlad Ratziu's enlightening insights on the latest nomenclature and definitions for steatotic liver disease. Discover why the medical community is adopting a new, inclusive language for Non-Alcoholic Fatty Liver Disease (NAFLD), now redefined to reflect its complex interplay with metabolic dysfunction and lifestyle factors.
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and its evolving terminology, diagnostic challenges, and association with cardio-metabolic syndrome. Learn about its progressive nature, the gold standard for diagnosis, and the emerging role of biomarkers. A must-read for healthcare professionals aiming for early diagnosis and effective management.
Unveiling the high prevalence of NAFLD and advanced fibrosis in type 2 diabetes patients - a deep-dive into two groundbreaking studies from the US and France. Explore the findings and their implications for future diabetes care.
On International NASH Day 2023, join Michael Betel of the Fatty Liver Alliance as he addresses NAFLD and NASH, their prevalence and impact. Discover solutions including medical education, patient awareness, and advocacy. Learn about the Alliance's future goals.
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic steatohepatitis (NASH) with insights from Dr Giada Sebastiani, associate professor of medicine at McGill University Health Center in Canada.
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient in order for improved patient outcomes.
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including nutrition and exercise. He shows that weight loss is associated with NASH resolution and fibrosis regression over time following bariatric surgery in patients with severe obesity and NASH.
This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom, and Prof. Sven Francque, along with chair, Prof. Stefan Anker. They review the epidemiology of NAFLD / NASH, its increasing prevalence rates, and discuss current best practices to improve patient outcomes.
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.
Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.